Table 2

Summary: Breast cancer responses

Clinical, radiological, and pathological measurements of greatest tumor diameter in cm. Histopathological tumor type at diagnosis and axillary nodal status at dissection are presented (0, all axillary lymph nodes were negative). HCFs as percentage of cancer area within the tumor sections are shown to compare the calculated percentage of residual tumor volume (radiology alone) and cancer volume (radiology with histology). Cumulative apoptotic and mitotic cellular response values are the sum of the change in index for all time points (days 1 to 4), relative to day 0.

Patient nos.
1234567891011
Diameters (cms) (Post:Pre)a
Clinical4.5:6.05.0:5.05.0:6.05.0:9.02.0:4.02.0:4.00:2.50:15.00:7.50:6.00:5.0
Mammography4.5:4.74.5:4.33.0:3.53.0:NA1.7:2.43.6:4.51.4:2.74.5:8.03.0:3.70:2.52.3:3.7
Ultrasound3.4:2.83.4:3.22.1:2.72.7:4.31.1:2.01.2:2.21.2:2.3NA3.2:2.50:2.22.2:2.9
Pathology3.23.7NAb4.51.82.01.26.2c2.00.20
Histological typeIDCIDCMIDCIDCIDCIDCIDCIDCIDCIDCIDC
Axillary LNs (+)7/170NAb1/15d2/29000000
HCF% (Post:Pre)30:3090:70NA30:5050:7010:3030:7050:5030:3030:300:30
Clin-Path outcomeeSDSDSDPRPRPRPRPRPRMiRDPCR
Residual volume
Tumor (%)100905524204599109020
Cancer (%)100116551414154910900
Cell responses
Apoptotic5411131212141161515
Mitotic571944112202611421211222
  • a Post:Pre, posttreatment:pretreatment; LNs, lymph nodes; IDC, invasive ductal carcinoma; IDCM, IDC with medullary features.

  • b Pathologic findings were not available because this patient deferred surgery until after she had completed another course of Adriamycin-containing chemotherapy.

  • c Aggregate diameter measurement from 18 microscopic foci of cancer.

  • d One micrometastasis only.

  • e Clinico-pathologic (Clin-Path) outcome is the assessment of the tumor response as: SD, stable disease (<50% diameter reduction); PR, partial response (≥50% diameter reduction); MiRD, microscopic pathologic residual disease as a single focus (3 mm); and PCR, pathologic complete response (no histologic cancer at resection).